Silveira Felipe Dantas, Gomes Francisco Isaac Fernandes, do Val Danielle Rocha, Freitas Hermany Capistrano, de Assis Ellen Lima, de Almeida Diana Kelly Castro, Braz Helyson Lucas Bezerra, Barbosa Francisco Geraldo, Mafezoli Jair, da Silva Marcos Reinaldo, Jorge Roberta Jeane Bezerra, Clemente-Napimoga Juliana Trindade, Costa Deiziane Viana da Silva, Brito Gerly Anne de Castro, Pinto Vicente de Paulo Teixeira, Cristino-Filho Gerardo, Bezerra Mirna Marques, Chaves Hellíada Vasconcelos
Graduate Programme in Health Sciences, Federal University of Ceará, Sobral, Brazil.
Faculty of Dentistry, Federal University of Ceará, Sobral, Brazil.
Front Neurosci. 2022 Apr 25;16:742239. doi: 10.3389/fnins.2022.742239. eCollection 2022.
possesses multiple biological effects and the 4-[(4'--acetyl-α-L- rhamnosyloxy) benzyl] isothiocyanate accounts for them. Based on the original isothiocyanate molecule we obtained a semisynthetic derivative, named 4-[(2',3',4'--triacetyl-α-L-rhamnosyloxy) -benzyl] hydrazine carbothioamide (MC-H) which was safe and effective in a temporomandibular joint (TMJ) inflammatory hypernociception in rats. Therefore, considering that there is still a gap in the knowledge concerning the mechanisms of action through which the MC-H effects are mediated, this study aimed to investigate the involvement of the adhesion molecules (ICAM-1, CD55), the pathways heme oxygenase-1 (HO-1) and NO/cGMP/PKG/K , and the central opioid receptors in the efficacy of the MC-H in a pre-clinical study of TMJ pain.
Molecular docking studies were performed to test the binding performance of MC-H against the ten targets of interest (ICAM-1, CD55, HO-1, iNOS, soluble cGMP, cGMP-dependent protein kinase (PKG), K channel, mu (μ), kappa (κ), and delta (δ) opioid receptors). In studies, male rats were treated with MC-H 1 μg/kg before TMJ formalin injection and nociception was evaluated. Periarticular tissues were removed to assess ICAM-1 and CD55 protein levels by Western blotting. To investigate the role of HO-1 and NO/cGMP/PKG/K pathways, the inhibitors ZnPP-IX, aminoguanidine, ODQ, KT5823, or glibenclamide were used. To study the involvement of opioid receptors, rats were pre-treated (15 min) with an intrathecal injection of non-selective inhibitor naloxone or with CTOP, naltrindole, or norbinaltorphimine.
All interactions presented acceptable binding energy values (below -6.0 kcal/mol) which suggest MC-H might strongly bind to its molecular targets. MC-H reduced the protein levels of ICAM-1 and CD55 in periarticular tissues. ZnPP-IX, naloxone, CTOP, and naltrindole reversed the antinociceptive effect of MC-H.
MC-H demonstrated antinociceptive and anti-inflammatory effects peripherally by the activation of the HO-1 pathway, as well as through inhibition of the protein levels of adhesion molecules, and centrally by μ and δ opioid receptors.
具有多种生物学效应,4-[(4'-乙酰-α-L-鼠李糖氧基)苄基]异硫氰酸酯是其产生这些效应的原因。基于原始的异硫氰酸酯分子,我们获得了一种半合成衍生物,名为4-[(2',3',4'-三乙酰-α-L-鼠李糖氧基)-苄基]肼基硫代甲酰胺(MC-H),它在大鼠颞下颌关节(TMJ)炎性痛觉过敏中安全有效。因此,鉴于关于MC-H发挥作用的机制仍存在知识空白,本研究旨在在TMJ疼痛的临床前研究中探究黏附分子(ICAM-1、CD55)、血红素加氧酶-1(HO-1)和NO/cGMP/PKG/K通路以及中枢阿片受体在MC-H疗效中的作用。
进行分子对接研究以测试MC-H与十个感兴趣靶点(ICAM-1、CD55、HO-1、诱导型一氧化氮合酶(iNOS)、可溶性环鸟苷酸(cGMP)、环鸟苷酸依赖性蛋白激酶(PKG)、钾通道、μ、κ和δ阿片受体)的结合性能。在实验中,雄性大鼠在TMJ注射福尔马林前用1μg/kg的MC-H进行处理,并评估痛觉感受。去除关节周围组织,通过蛋白质印迹法评估ICAM-1和CD55蛋白水平。为了研究HO-1和NO/cGMP/PKG/K通路的作用,使用了抑制剂锌原卟啉IX(ZnPP-IX)、氨基胍、1H-[1,2,4]恶二唑并[4,3-a]喹喔啉-1-酮(ODQ)、N-[2-[[4-(氯苯基)苯基]甲基]硫代]-N,N'-二甲基脲(KT5823)或格列本脲。为了研究阿片受体的作用,大鼠经鞘内注射非选择性抑制剂纳洛酮或经处理(15分钟)使用环丙甲羟二氢吗啡酮(CTOP)、纳曲吲哚或诺宾那托啡。
所有相互作用均呈现出可接受的结合能值(低于-6.0千卡/摩尔),这表明MC-H可能与其分子靶点强烈结合。MC-H降低了关节周围组织中ICAM-1和CD55的蛋白水平。ZnPP-IX、纳洛酮、CTOP和纳曲吲哚逆转了MC-H的镇痛作用。
MC-H通过激活HO-1通路以及抑制黏附分子蛋白水平在周围发挥镇痛和抗炎作用,并通过μ和δ阿片受体在中枢发挥作用。